Questcor Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Questcor Pharmaceuticals, Inc.
FDA reviewers stuck to established assessment practices during the coronavirus crisis and produced one of the agency’s largest yearly novel approval counts ever.
Public Company Edition: Lilly’s COVID-19 antibody partner AbCellera launched one of the biggest IPOs of 2020, bringing in $483m. Also, two more SPACs went public; Sinovac, Biocryst and Kura Oncology arranged large financings; and Viatris plans post-merger layoffs.
Keeping Track: Orladeyo, Danyelza, Imcivree Bring CDER 2020 Novel Approval Count Even With Full-Year 2019
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
The long-acting neuromodulator improved symptoms of cervical dystonia in a Phase III trial with longer duration of efficacy versus older products; a launch for aesthetics is expected soon.
- Other Names / Subsidiaries
- BioVectra Inc.